Pure Global AI
NCT06334406Not yet recruiting

Antitumor T Cell Responses in Patients With Bladder Cancer

Study of Antitumor T Cell Immune Responses in Patients With Bladder Cancer
Centre Hospitalier Universitaire de BesanconClinicalTrials.govother
Verified
Study focus
Disease/Condition
Bladder Cancer
Drug/Device/Intervention
Biological samples
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Centre Hospitalier Universitaire de Besancon
Timeline & enrollment
Phase
N/A
Start date
Apr 02, 2024
End date
Apr 02, 2026
Enrollment
33 participants
Primary outcome

Tumor antigen specific T-cell responses

Summary

The main objective of this study is to evaluate the induction of Th1 anti-TERT responses by
 treatments in patients with bladder tumor.

ICD-10 classifications
Malignant neoplasm of bladderMalignant neoplasm: Bladder, unspecifiedMalignant neoplasm: Dome of bladderMalignant neoplasm: Overlapping lesion of bladderMalignant neoplasm: Lateral wall of bladder
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06334406
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06334406 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre Hospitalier Universitaire de Besancon and is currently Not yet recruiting. The study focuses on Bladder Cancer. Target enrollment is 33 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.